Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Highly Accessed Research article

Biomarkers of apoptosis and survival in esophageal squamous cell carcinoma

Mikiko Takikita1, Nan Hu2, Jian-zhong Shou3, Quan-Hong Wang4, Carol Giffen5, Philip R Taylor2* and Stephen M Hewitt1*

Author Affiliations

1 Tissue Array Research Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

2 Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

3 Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, PR China

4 Shanxi Cancer Hospital, Taiyuan, Shanxi, PR China

5 Information Management Services, Inc, Silver Spring, MD, USA

For all author emails, please log on.

BMC Cancer 2009, 9:310  doi:10.1186/1471-2407-9-310

Published: 3 September 2009

Abstract

Background

Cancer of the esophagus is a deadly malignancy, and development of biomarkers that predict survival is an urgent need. The apoptotic pathways have been hypothesized as important in progression of esophageal squamous cell carcinoma (ESCC). We investigated a panel of proteins that regulate apoptosis as candidate of biomarkers of prognosis in ESCC.

Methods

Tissue microarray (TMA) including 313 surgically-resected cases of ESCC specimens was built for immunohistochemical interrogation. We evaluated seven genes in the FasL-Fas apoptotic pathway - FasL, Fas, FAS-associated death domain protein (FADD), phosphorylated-FADD, and caspase 8 and 10, and the antiapoptotic protein bcl-2. We studied pathway integrity and relations to risk and clinical factors, and determined the prognostic significance of each marker.

Results

Five markers showed strong inter-marker correlations (r ≥ 0.28, p < 0.001), including FasL, Fas, FADD, and caspases 8 and 10. FasL and FADD also showed modest correlations with one or more cancer risk factors, but none of the markers was significantly associated with either tumor stage or lymph node metastasis, the only two clinical factors that predicted survival in these ESCC cases. Multivariate-adjusted proportional hazard regression models showed no association between protein expression and risk of death for any of the seven markers examined.

Conclusion

Individual biomarkers in the apoptosis pathway do not appear to predict survival of patients with ESCC.